Japan's Chugai Sees Avastin Sales Of Y7 Billion By End-March 2008 (Japan)
This article was originally published in PharmAsia News
Chugai Pharmaceutical Co. expects cancer drug Avastin to generate sales of around Y7 billion in the nine months from July to the end of March 2008. Swiss drugmaker Roche Holding AG owns a majority stake in Chugai. The Japanese government has set the price for Avastin at Y50,291 for a 100 milligram dose. The price was lower than what analysts had expected for the drug, which hinders the growth of tumors by starving them of blood supply. Avastin was approved by the Japanese Ministry of Health, Labor and Welfare last month for the treatment of advanced or refractory colorectal cancer. Despite the lower-than-expected price, analysts are still predicting that Avastin will become a blockbuster drug in Japan, saying it will gain approval for use in other cancers. (Click here for more - May Require Paid Subscription
You may also be interested in...
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.
Coronavirus Update: Roche Launches Remdesivir Plus Actemra Trial, GSK Plans 1bn Vaccine Adjuvant Doses
Roche is teaming up with Gilead on the combination trial, aiming to improve on results of remdesivir alone, which has failed to show mortality benefits in COVID-19 patients.